I agree. The main share price overhang right now is the future need for capital, and uncertainty as to where it will come from. Potential investors are more worried about economics than they are interested in the promise of the science.
Plenty of initiating trials and IND submissions there. Not to mention half these were expected last year. I'm curious on NSCLC HOT data, but that's about it at this point.
The market is done with Advaxis until they can show partnerships with real cash to run all these trials... instead of diluting and destroying shareholders every chance they get.
Where's the money!? 20 years of operation and here they are... barely a P1.
Just 'expectations'. Let us see which way it translates (reality). Till then it means nothing. Will ISTs and initiation of trials propel the stock into high single digit which is still < $1 in pre-split terms?; or is the company going to thrust the begging bowl again some time early spring of next year to get more money using these trials as an excuse. (assuming it is not going to be de listed).
Stock is undervalued ? - OK; then let us wait for EOY to see how nicely it appreciates given the catalysts. After all that is what catalysts are supposed to do.
Even better would be to wait for the '2020 Business Plan' and see if any 2019 'Great Expectations' have been pushed to 2020.
News 
Market Data 
Discover 
